QIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics with Next-Generation Sequencing (NGS) Technologies; Full Acquisition Completed for $150 Million

On January 10, 2023, QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) announced that it has completed the acquisition of Verogen, a leader in the use of next-generation sequencing (NGS) technologies to drive the future of human identification (HID) and forensic investigation. Verogen, a privately held company founded in 2017 and based in San Diego, supports the global human identification community with NGS tools and professional services to help resolve criminal and missing-persons cases. QIAGEN and Verogen have been commercialization partners since announcing a distribution agreement in June 2021. QIAGEN--which in the late 1990s launched the first commercial kits to purify DNA from forensic casework samples--already has a leading position in the HID / forensics market. QIAGEN’s sample collection and preparation kits, genetic testing analysis, and workflow automation products are used around the world by forensic science laboratories and criminal investigators.

Login Or Register To Read Full Story